The recent federal action directing the FDA to accelerate the review of psychedelic therapies marks a major shift in the development of next-generation mental health treatments. With regulatory timelines compressing and new federal support behind this category, compounds such as psilocybin and ibogaine are moving closer to broader clinical use.

For a field that remained largely dormant for decades, this moment represents a clear turning point.

“This is an inflection point for psychedelic research,” said Bonnie Segal, President of Segal Trials. “The science has been building for years, but now the timelines are accelerating. As that happens, execution becomes everything. Experienced sites that already know how to run these studies safely and effectively are going to be critical.”

While federal momentum is growing, site-level readiness remains a key constraint. Psychedelic trials require purpose-built environments, highly trained facilitators, extended dosing oversight, and strong operational control—capabilities that take years to establish.

Segal Trials has spent more than six years building the expertise and regulatory experience required to operate in this space. Through its Center for Psychedelic Research, the organization has supported studies across depression, treatment-resistant depression, PTSD, premenstrual dysphoric disorder, and generalized anxiety disorder.

Since entering the field in 2018, Segal Trials has completed more than 60 psychedelic dosing sessions and has worked across seven DEA Schedule I compounds, including psilocybin, LSD, DMT, 5-MeO-DMT, and MDMA. The organization also operates three purpose-built dosing rooms and a specialized team trained in complex psychedelic protocols.

“Psychedelic trials are fundamentally different from traditional CNS studies,” said Dr. Rishi Kakar, Chief Scientific Officer and Medical Director of Segal Trials. “They require extended patient monitoring, careful clinical coordination, and experienced teams that understand both the medical and operational complexity involved.”

As development accelerates, the ability to execute studies safely, efficiently, and at scale will define the next phase of this field. Segal Trials remains positioned to support sponsors navigating this shift and advancing psychedelic therapies into mainstream clinical research.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260422718683/en/

“The science has been building for years, but now the timelines are accelerating. As that happens, execution becomes everything. Experienced sites that already know how to run these studies safely and effectively are going to be critical.”